We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Maier, HW. L’ergotamine inhibitteur du sympathique étudie enclinique, comme moyen d’exploration et comme agent therapeutique. Rev Neurol. 1926;33:1104–08.Google Scholar
2
2.Doenicke, A, Brand, J, Perrin, VL. Possible benefit of GR43175, anovel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. The Lancet. 1988;11:1309–11.CrossRefGoogle Scholar
3
3.Ferrari, MD, Roon, KI, Lipton, RB, et al.Oral tripans (Serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. The Lancet. 2001;358:1668–75.CrossRefGoogle Scholar
4
4.Pilgrim, AJ. Methodology of clinical trials of sumatriptan inmigraine and cluster headache. Eur Neurol. 1991;31:295–9.CrossRefGoogle ScholarPubMed
5
5.Cady, RK, Sheftell, F, Lipton, RB, et al.Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther. 2000;22:1035–48.CrossRefGoogle ScholarPubMed
6
6.Burstein, R, Collins, B, Jakubowski, M. Defeating migraine pain withtriptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19–26.CrossRefGoogle ScholarPubMed
7
7.Pascual, J. Clinical benefits of early triptan therapy for migraine. Headache. 2002;42 Suppl 1:S10–7.CrossRefGoogle ScholarPubMed
8
8.Jelinski, SE, Becker, WJ, Christie, SN, et al.Pain free efficacy of sumatriptan in the early treatment of migraine. Can J Neuro Sci. 2006;33:73–9.CrossRefGoogle ScholarPubMed
9
9.Edmeads, J. The treatment of headache: a historical perspective. In: Gallagher, RM, editor. Drug Therapy for Headache. New York: Marcel Dekker Inc; 1990. p. 108.Google Scholar